Eli Lilly and Company (NYSE:LLY) Shares Purchased by PFC Capital Group Inc.

PFC Capital Group Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 0.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,290 shares of the company’s stock after acquiring an additional 40 shares during the quarter. Eli Lilly and Company accounts for about 2.3% of PFC Capital Group Inc.’s portfolio, making the stock its 12th biggest holding. PFC Capital Group Inc.’s holdings in Eli Lilly and Company were worth $4,855,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in LLY. Geode Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company’s stock valued at $13,389,651,000 after purchasing an additional 291,875 shares during the last quarter. National Wealth Management Group LLC lifted its stake in Eli Lilly and Company by 19.0% during the fourth quarter. National Wealth Management Group LLC now owns 326 shares of the company’s stock valued at $252,000 after buying an additional 52 shares in the last quarter. Nemes Rush Group LLC boosted its holdings in shares of Eli Lilly and Company by 6.3% in the fourth quarter. Nemes Rush Group LLC now owns 14,141 shares of the company’s stock worth $10,917,000 after buying an additional 835 shares during the period. Gibson Capital LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $264,000. Finally, Family Legacy Inc. raised its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Family Legacy Inc. now owns 7,915 shares of the company’s stock valued at $6,231,000 after acquiring an additional 217 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on LLY shares. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Citigroup dropped their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Bank of America reiterated a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Finally, Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,009.72.

Eli Lilly and Company Stock Up 0.4 %

Shares of LLY stock opened at $825.42 on Tuesday. The stock’s 50 day simple moving average is $846.30 and its 200 day simple moving average is $835.00. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a market capitalization of $782.64 billion, a price-to-earnings ratio of 70.49, a PEG ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its Board of Directors has approved a stock buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.